Amicus picks Brammer for preclinical, clinical gene therapy work 02-Jul-2019 By Vassia Barba Rare disease drug developer to work with Brammer Bio – which Thermo Fisher acquired in March – on gene therapy programs against Batten disease.
Thermo Fisher ups clinical, commercial capabilities with $50m investment 25-Apr-2019 By Melissa Fassbender Thermo Fisher Scientific is investing $50m to further expand its biologic drug substance capabilities for both clinical and commercial supply.
Brammer acquisition bolsters Thermo Fisher place in the market 29-Mar-2019 By Maggie Lynch Thermo Fisher’s $1.7bn acquisition bolsters its ‘already strong position’ in the cell and gene therapy market, with increased CDMO capabilities.
Thermo Fisher acquires gene therapy CDMO Brammer Bio 25-Mar-2019 By Maggie Lynch Thermo Fisher Scientific bolsters its gene therapy capabilities by acquiring Brammer Bio for $1.7bn, as the market becomes an ‘increasing focus’ for customers.
Brammer Bio advancing 3 year, $200m program: 700 employees expected by mid-2019 27-Sep-2018 By Melissa Fassbender Brammer Bio’s three-year, $200m investment program is set to establish more than 30 suites for both clinical and commercial viral vector supply.
